FDA Approves Ready-to-Use Aprepitant Injectable Emulsion for CINV

The U.S. Food and Drug Administration (FDA) has approved Aprepitant Injectable Emulsion. This approval introduces a practical, administration-friendly intravenous (IV) antiemetic designed to simplify the treatment preparation process for healthcare providers and enhance the patient experience.

For oncology nurses, the approval of this ready-to-use formulation addresses several clinical hurdles commonly encountered in the delivery of chemotherapy. By providing a stable, pre-mixed emulsion, the therapy eliminates the need for reconstitution, thereby reducing preparation steps and potential errors in high-acuity oncology settings.

Clinical indications and mechanism of action

Aprepitant Injectable Emulsion is a neurokinin-1 (NK1) receptor antagonist. It works by blocking the action of neurokinin, a substance in the brain that triggers the nausea and vomiting reflex. This agent is indicated for use in combination with other antiemetic agents in adults for the prevention of

• Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC), including high-dose cisplatin, administered as a single-dose regimen.
• Delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC), also as a single-dose regimen.
• Nausea and vomiting associated with initial and repeat courses of MEC when administered as a 3-day regimen.

It is important for clinicians to note that this agent has not been studied for the treatment of established nausea and vomiting; its role is strictly prophylactic.

A simplified formulation for clinical efficiency

One of the most notable features of this new approval is its "ready-to-use" status. Unlike many existing antiemetics that require complex reconstitution or dilution before administration, this emulsion is designed for direct IV use. This streamlined process allows nurses to focus more time on direct patient care and monitoring.

Furthermore, the formulation specifically avoids the use of polysorbate-80. Polysorbate-80 is a synthetic surfactant often used in injectable drugs that has been associated with hypersensitivity reactions in some patients. By removing this component, the new aprepitant formulation offers a critical alternative for patients who have demonstrated sensitivities to surfactants.

Safety and nursing monitoring parameters

Oncology nurses must remain vigilant regarding the safety profile and drug-drug interactions associated with aprepitant. The agent is a substrate, a dose-dependent inhibitor, and an inducer of CYP3A4.

Key nursing considerations include:

• Contraindicated Medications: Aprepitant is contraindicated in patients taking pimozide. The inhibition of CYP3A4 can lead to elevated plasma concentrations of pimozide, potentially causing life-threatening QT prolongation.
• Warfarin Management: Coadministration with warfarin (a CYP2C9 substrate) may lead to a clinically significant decrease in the International Normalized Ratio (INR). Nurses should monitor the INR in patients on chronic warfarin for two weeks following each aprepitant cycle, with a focus on the 7-to-10-day mark.
• Contraceptive Efficacy: The efficacy of hormonal contraceptives may be reduced during treatment and for 28 days following the last dose. Nurses should advise patients to use effective non-hormonal back-up methods of contraception.
• Hypersensitivity Reactions: Serious reactions, including anaphylaxis, have been reported. Patients should be monitored during and immediately following administration for symptoms such as dyspnea, eye swelling, flushing, and wheezing.The most common adverse reactions associated with aprepitant therapy include fatigue, headache, diarrhea, neutropenia, and anemia.

Expanding access to supportive care

The approval highlights the utility of the 505(b)(2) regulatory pathway, which allows companies to optimize established therapies into more practical formats. Ronald L. Scarboro, CEO of Azurity Pharmaceuticals, emphasized in a news release that this innovation aligns with the "realities of patient care" by providing a reliable, ready-to-use choice for the oncology community.

As chemotherapy continues to be a physically and emotionally taxing experience for patients, the availability of simplified, polysorbate-free supportive care options represents a significant advancement in oncology nursing practice.

Reference

Azurity Pharmaceuticals. Azurity Pharmaceuticals Announces FDA Approval of Aprepitant Injectable Emulsion, Expanding Access to Critical Supportive Oncology Care. News release. June 25, 2026. Accessed June 29, 2026.